What we stand for


endsulin is a start-up company with to cure Type I Diabetes with Gene Therapy. Hans Sollinger, MD has discovered and patented a DNA sequence which is glucose responsive and promotes the activation of the human insulin gene in a physiological fashion. This gene is called Diatagene. They are the first ones to publish data demonstrating that glucose control, and insulin disappearance after glucose stimuli, follow an absolute perfect physiological pattern. Work performed in 2013 is focused on improvements of gene delivery and long-term expression. With approximately 5 million Type I diabetics in developed nations, there is a huge potential market as diabetics would require only a one-time single injection, and are expected to have much better glucose control.

Our Management Team


    MR. JAY. W. HANDY Acting CEO

    Jay is the Acting CEO of an investment management company. Prior to starting this company, Jay served as managing director of Merrill Lynch in Madison, WI. He has partaken in many national forums on diabetes, including HHS Secretary Tommy Thompson’s diabetes health initiatives. He is a graduate of Michigan State University and Harvard Business School. Jay has managed his own diabetes for 40 years.